| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CRF2X; CRF2-10; CRF2-S1; IL-22BP; IL-22RA2; ZCYTOR16; IL-22R-alpha-2 |
| WB Predicted band size | 31 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human IL22RA2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于IL22RA2抗体的代表性文献(信息简化版)：
1. **"IL-22RA2 is a novel target for therapeutic antibodies in allergic diseases"**
*作者：Smith A et al. (2021)*
摘要：研究开发了靶向IL-22RA2的单克隆抗体，发现其通过阻断IL-22信号异常活化显著减轻小鼠模型中过敏性哮喘的气道炎症，提示其作为过敏性疾病治疗的潜力。
2. **"Anti-IL22RA2 antibody attenuates psoriasis-like skin inflammation via regulating Th17 response"**
*作者：Chen L et al. (2019)*
摘要：该研究证明IL22RA2抗体通过抑制IL-22/STAT3通路，减少银屑病模型中Th17细胞浸润和角质细胞过度增殖，为银屑病治疗提供新策略。
3. **"IL22RA2 as a biomarker for colorectal cancer progression and antibody-based targeting"**
*作者：Garcia-Ruiz C et al. (2020)*
摘要：首次报道IL22RA2在结直肠癌组织中高表达，其抗体可抑制肿瘤细胞迁移并增强化疗敏感性，提示其作为预后标志物和治疗靶点的双重价值。
注：以上文献为示例性内容，实际研究中请通过PubMed等平台检索具体文献(搜索关键词：IL22RA2 antibody + disease/therapy)。
IL22RA2. also known as interleukin-22 receptor subunit alpha-2 or IL-22 binding protein (IL-22BP), is a soluble receptor homolog that modulates the activity of IL-22. a cytokine involved in inflammatory responses and tissue repair. Unlike the membrane-bound IL-22 receptor complex (IL-22RA1/IL-10Rβ), IL22RA2 lacks a transmembrane domain and functions as a decoy receptor. It binds IL-22 with high affinity, competitively inhibiting its interaction with the signaling receptor, thereby attenuating IL-22-mediated pathways such as STAT3 activation. This regulatory mechanism positions IL22RA2 as a critical player in balancing IL-22's roles in mucosal immunity, epithelial homeostasis, and pathological inflammation.
Antibodies targeting IL22RA2 are valuable tools for studying its expression, distribution, and interaction dynamics with IL-22. They enable researchers to explore IL22RA2's involvement in diseases like psoriasis, inflammatory bowel disease (IBD), rheumatoid arthritis, and cancer, where IL-22 signaling is dysregulated. Therapeutic antibodies against IL22RA2 are under investigation to either block its decoy activity (enhancing IL-22's protective effects) or stabilize its binding to IL-22 (reducing excessive inflammation). Such strategies hold potential for treating conditions characterized by IL-22 imbalance. However, the dual role of IL-22 in both tissue repair and inflammation necessitates careful evaluation of antibody-based interventions to avoid unintended outcomes. Current research focuses on optimizing specificity and pharmacokinetics to advance these antibodies toward clinical applications.
×
